Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act [PDF]
With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity.
Frank R. Lichtenberg, Joel Waldfogel
core
Retinoid receptors in ovarian cancer: expression and prognosis [PDF]
Background: Ovarian cancer is frequently lethal despite aggressive multimodal therapy, and new therapies are therefore needed. Retinoids are potential candidate drugs: they prevent the development of ovarian carcinoma and enhance the efficacy of ...
Aebi, S. +3 more
core
Retinoids and Rexinoids in Cancer Prevention: From Laboratory to Clinic [PDF]
Brown, Powel H. +2 more
core +1 more source
Brain Single-Cell Transcriptional Responses to Bexarotene-Activated RXR in an Alzheimer's Disease Model. [PDF]
Saibro-Girardi C +5 more
europepmc +1 more source
Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series. [PDF]
Dobos G +6 more
europepmc +1 more source
Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report. [PDF]
Shimada N +5 more
europepmc +1 more source
Orthogonal Temperature-Related Intensity Change and Time-Resolved Förster Resonance Energy Transfer High-Throughput Screening Platform for the Discovery of SLIT2 Binders. [PDF]
García-Vázquez N +2 more
europepmc +1 more source
Exploring the Regulation of <i>Tmem182</i> Gene Expression in the Context of Retinoid X Receptor Signaling. [PDF]
Khilji S, Hamed M, Chen J, Li Q.
europepmc +1 more source

